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Abstract
Increased mucosal polyamine levels and ornithine decarboxylase (ODC) activity are associated
with an increased risk of colorectal neoplasia, and aspirin treatment reduces risk. Previous studies
suggest that a single nucleotide polymorphism (SNP) in the promoter of the ODC gene
(rs2302615) may be associated with adenoma risk and/or response to aspirin chemoprevention.
However, a comprehensive investigation of common genetic variation in the region of ODC gene
is lacking. Using a tag SNP approach, we investigated associations between genotype or haplotype
and adenoma risk among a cohort of 792 white non-Hispanic participants in a randomized trial of
aspirin. Generalized linear regression was used to compute relative risks (RRs) and 95%
confidence intervals (95% CIs) adjusted for age and sex. The false discovery rate was used to
account for multiple testing. Interactions terms were used to assess whether genotype modified the
effect of aspirin treatment. Of 15 SNPs analyzed, 7 were statistically significantly associated with
adenoma risk. However, in multiple SNP regression models, only 2 of these, located downstream
of the gene, were independently associated with risk: rs11694911 (1.29 RR, 1.08–1.53 95% CI,
P=0.005) and rs2430420 (1.20 RR, 1.03–1.40 95% CI, P=0.022). In addition, there was evidence
that rs2430420 and rs28362380 modified the effect of aspirin treatment, whereas the previously
investigated SNP, rs2302615, had no statistically significant main effect or interaction with aspirin
treatment. Our findings suggest that common genetic variants located downstream (3’) of the
ODC gene influence risk of colorectal adenoma and may also impact the efficacy of aspirin
chemoprevention.
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INTRODUCTION
Colorectal cancer is the second leading cause of cancer death in the United States (1) and is
potentially preventable. Modification of diet and lifestyle factors as well as the use of
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chemoprevention strategies in combination with screening may reduce the burden of this
disease (2, 3). Substantial evidence from meta-analyses of randomized clinical trials indicate
that aspirin is effective for prevention of colorectal cancer (4) and adenomas (the precursor
to most cancers) (5) and potentially cost-effective (6), although its effect may be modest.
However, in a recent randomized clinical trial, a combination of the ornithine decarboxylase
(ODC) inhibitor difluoromethylornithine (DFMO) and the non-steroidal anti-inflammatory
drug (NSAID) sulindac, was remarkably effective in reducing the occurrence of colorectal
adenomas: all adenomas were reduced by 70% and advanced lesions by more than 90% (7).
ODC is a key regulatory enzyme for the synthesis of polyamines, small highly regulated
molecules that are essential for cell growth and for the regulation of numerous processes,
including gene expression and ion channel activity (8). ODC catalyzes the first step in
polyamine biosynthesis, the conversion of ornithine to putrescine (9). Although the
association of increased polyamine synthesis (10, 11) and inflammation (12, 13) with
colorectal carcinogenesis has been recognized for some time, the striking results of the
DFMO/sulindac trial highlight the potential for an effective combination chemoprevention
strategy (14). Given the mandate to use pharmacogenomics to personalize cancer treatment
(15) and presumably prevention, it will be important to investigate the potential effect of
common genetic variation on such a strategy.
Several previous genetic epidemiological studies of a single nucleotide polymorphism
(SNP) in the ODC gene (rs2302615) suggested that the variant allele may be associated with
a decreased risk for adenoma recurrence and/or an enhanced response to aspirin use or
treatment (16–18). However, in the DFMO/sulindac trial the variant allele appeared to be
associated with a reduced response to treatment (19). In addition, it was associated with
reduced survival in a cohort of colorectal cancer patients (20). Regardless, a major limitation
of this prior work is that only one common SNP in the ODC gene has been investigated to
date. The goal of the present study was to extend this work to investigate associations with
adenoma risk and response to aspirin chemoprevention of common genetic variation
throughout the ODC gene and adjacent chromosomal regions.
MATERIALS AND METHODS
Study Design and Population
We performed a cohort analysis of the association between ODC1 genotypes and colorectal
adenoma recurrence among participants in the Aspirin/Folate Polyp Prevention Study, a
double-blind, placebo-controlled, randomized clinical trial of aspirin and/or folic acid for the
prevention of colorectal adenoma recurrence (21, 22). Human subjects committees at each
of the clinical centers approved the study protocol and materials distributed to participants
and all participants provided written informed consent. The study design and main findings
have been described in detail previously (21, 22). In brief, eligible participants had no
history of colorectal cancer or any familial cancer syndrome but had a recent history of one
or more histologically confirmed colorectal adenoma and a complete colonoscopy within 3
months prior to enrollment with all polyps removed from the bowel. Subjects, who agreed to
avoid NSAID use during their participation in the study, were randomized to aspirin
treatment (placebo, 81 or 325 mg daily) and independently to folic acid treatment (placebo
or 1 mg daily) in a 3 X 2 factorial design. Aspirin treatment was continued for an average of
almost three years (33 months) until a follow-up colonoscopy was performed. The principal
outcome of the study was the occurrence of at least one adenoma during randomized
treatment. To maximize outcome ascertainment, we included findings from colonoscopies
that were performed at least one year after randomization and on or before September 28,
2001, as described in the publication of the main study findings (21). Thus, the actual
follow-up period ranged from 19 to 59 months post randomization. A single, blinded, study
pathologist provided uniform review of all clinical samples removed from the large bowel.
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SNP Selection and Genotyping
To provide comprehensive coverage of the ODC1 gene and adjacent potentially regulatory
regions, SNPs within 10 kb upstream and 10 kb downstream of the gene were chosen for
genotyping using data from four sources. Two of the sources are publically available
databases: the HAPMAP - CEU population (Utah residents with Northern and Western
European ancestry from the CEPH collection from NCBI release #36; see (23)) and the
NIEHS SNPs (National Institute of Environmental Health Sciences Environmental Genome
Project; see (24)). In addition, some SNPs were chosen that were not included in either of
the public databases, based on frequency data obtained from more comprehensive
genotyping of CEPH samples (N=90) and a sample of 81 participants in the DFMO/sulindac
trial (7) [data shared by Drs. Eugene Gerner and Patricia Thompson from the Arizona
Cancer Center (Tucson, AZ)]. Because “binning” of SNPs with r2 ≥ 0.8 was inconsistent
across the 4 sets of genotyping data, all SNPs with a minor allele frequency (MAF) ≥ 3%
were genotyped and tag SNPs that were identified after genotyping of the current population
were chosen for analyses (see below).
Genomic DNA was isolated as previously described (17, 25). Genotyping was performed by
McGill University and Genome Quebec Innovation Center (Montreal, Canada) using
Sequenom iPLEX Gold technology according to the manufacturer’s instructions (Sequenom,
San Diego, CA) using a single panel. The oligos used are available upon request. Of a total
of 31 SNPs selected for genotyping, 2 were in GC rich regions and failed the initial
validation step and therefore were not genotyped (rs2302616 and rs28742580). The
remaining 29 SNPs had call rates ranging from 98.14 to 100% (median = 99.73%) and were
in Hardy Weinberg equilibrium (P>0.05 using a χ2 test for the comparison between observed
and expected genotype counts among white non-Hispanic subjects with no adenoma
recurrence). Concordance rates among 44 blinded duplicate samples was 100% for all SNPs
except for one (rs13000913), which had one error for a concordance rate of 97.7%. The
sample success rate was 99.0%; samples that could not be called at more than 3 of the 29
SNPs were deemed to have failed and were dropped from the analysis dataset. Of the
successful samples, 93.2% could be called at all SNPs and another 5.8% could be called at
all but one SNP. Of the 29 SNPs that were successfully genotyped, 13 were excluded from
the analyses because they were in high linkage disequilibrium (r2 ≥ 0.8) with a tag SNP
selected using Haploview Tagger (26), and 1 was excluded because it had a MAF less than
3% in our dataset. The excluded SNPs are: rs2463463, rs4669584, rs28362433, rs28362422,
rs2357550, rs1405948, rs3752661, rs2302613, rs2302614, rs12616336, rs7608353,
rs7558559, rs2009741, and rs6432097. Thus, a total of 15 tag SNPs are included in the
statistical analyses presented here along with rs2302615, which we genotyped previously
(17). Notably, rs2302615 is not in high linkage disequilibrium (r2 ≥ 0.8) with any of the
newly genotyped SNPs and thus meets the criteria for inclusion in these analyses as an
independent tag SNP.
Statistical Analysis
Of the total of 920 participants from the Aspirin/Folate Polyp Prevention Study with both
genetic data and trial end-point data available for this analysis, 128 (13.9%) reported a race/
ethnicity other than non-Hispanic white. Genotype was statistically significantly associated
with race for 8 of the 15 tag SNPs analyzed in our dataset (not shown) and race/ethnicity
may be associated with outcome [see (25)]. Therefore, we limited our analyses to
participants self-identified as “white, not of Hispanic origin” (N=792) because we did not
have adequate numbers of other racial/ethnic groups to appropriately address population
stratification (see Figure 1). The outcome assessed in these analyses was the recurrence of
one or more adenomas during randomized aspirin treatment. Because the asymptomatic
nature of this outcome prohibited time-to-event analysis, findings were assessed at follow-
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up colonoscopy. Risk ratios and 95% confidence intervals used to estimate the association
between genotype and adenoma recurrence were calculated with an underdispersed
generalized linear regression model using the Poisson distribution as an approximation to
the binomial family. Minimally adjusted (for age and sex) relative risks are shown in the
tables. Several levels of genotype association analyses were performed, as described below.
For SNP level analyses, genotypes were included in the regression equation one at a time
using an additive genetic model, providing per-allele relative risks and Wald test p-values
for the tables. To account for multiple statistical testing of 15 SNPs, false discovery rate
(FDR) q values were calculated (27) using the R statistical package (see (28)). Using this
FDR method we control the proportion of type I errors made rather than the probability of
making even a single type I error (i.e. 5% probability with the classical Bonferroni method
of multiple testing correction, which assumes independence of tests and thus is not
appropriate for genetic analyses within and around a single gene). We used an FDR
threshold of 20%, which has been suggested for candidate gene studies (29), such that up to
20% of the declared discoveries are expected to be false. In secondary analyses of
statistically significantly associated SNPs, genetic models (additive, dominant and recessive)
were examined for best fit using maximum likelihood-based statistics.
For haplotype level analyses, used to assess the combined effect of correlated SNPs, linkage
disequilibrium blocks were defined with Haploview (26) using the default algorithm based
on confidence bounds on D’ (30) (see Figure 2). Phased haplotype pairs and probabilities
were estimated with Powermarker v3.25 (31) using the EM algorithm (32). Generalized
linear regression was used to estimate the haplotype association with risk for adenoma
recurrence taking haplotype uncertainty (probability) into account. The haplotype was
modeled as a continuous variable wherein the number of copies of each allele was
multiplied by its probability to obtain a continuous variable. The most common haplotype
was used as the reference group and omitted from the model. For each haplotype, the model
provides an estimate of the risk associated with each additional copy of the specified
haplotype. The most frequent haplotypes (with frequencies above 3%) were analyzed
individually, and the remaining rare haplotypes were pooled. Wald test p values were
calculated for each individual haplotype and a likelihood ratio test p-value was calculated
for the joint contribution of all haplotypes to the model.
For gene level analyses, a multiple SNP test was used to assess which SNPs in this
chromosomal region were independently associated with risk of adenoma recurrence in an
exploratory data-driven analysis. Starting with a composite regression equation containing
all 16 tag SNPs, a step-down selection process was used in which SNP variables were
removed from the equation one at a time in order of decreasing likelihood ratio test p-values
until only SNPs with p-values <0.05 remained. A step-up approach gave the same results. A
global multiple degrees of freedom likelihood ratio test was used to assess the statistical
significance of the joint contribution of all independently associated SNPs to the model. In
addition, a composite genetic risk score was created for independently associated SNPs by
summing the number of risk genotypes over these loci.
We also evaluated whether aspirin treatment interacted with ODC genotypes to modify
associations with adenoma risk using interaction terms in the single SNP regression models
and Wald tests. Stratified analyses (by aspirin treatment group or by genotype) were used to
obtain stratum specific estimates of relative risk and confidence intervals. We did not
account for multiple testing in these analyses as we had limited power.
Analyses that included study treatment with aspirin or folate were conducted according to
the intention-to-treat principle. All statistical tests were two-sided and considered significant
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at a value of P < 0.05, except as otherwise indicated above. Stata (version 10) was used for
all analyses, except as described above.
RESULTS
Demographic and other selected characteristics of non-Hispanic white participants from the
Aspirin/Folate Polyp Prevention Study with genotypeand outcome data that were included in
the present analysis (see Figure 1) are presented in Table 1. Among the 792 participants, 370
(46.7%) had a recurrence of one or more colorectal adenomas during follow-up. The mean
age was almost 58 years and the majority of participants were males (64%). Approximately
39% of participants had a family history of colorectal cancer among first-degree relatives.
On average, participants were followed for 32.8 months from randomization to their follow-
up colonoscopy. As observed in the full analyses of the trial (21, 22), individuals who were
randomized to 81 mg/day of aspirin were less likely to have a recurrence compared with
those randomized to the placebo arm (P=0.04), whereas treatment with 325 mg/day aspirin
(P=0.83) or 1 mg/day folate (P=0.51) was not significantly associated with the outcome. In
addition, the main effect of aspirin in this subset of 792 participants (0.77 RR, 0.63–0.94
95% CI, P=0.009 for 81 mg aspirin and 0.99 RR, 0.82–1.19 95% CI, P=0.89 for 325 mg
aspirin) was similar to that for the entire cohort (21).
We first examined associations of common SNPs in the vicinity of the ODC1 gene with risk
of adenoma recurrence in single SNP analyses (Table 2). The region analyzed encompassed
about 23 kb in total: including approximately 7 kb upstream (5’) and 8 kb downstream (3’)
of the 8 kb transcribed region of the ODC1 gene. In Table 2, minor allele frequencies
(MAFs) and gene locations are shown for the SNPs that were included in the statistical
analyses, including 15 newly genotyped SNPs and rs2302615, which was genotyped
previously (17). Results for seven SNPs were statistically significant at a value of P < 0.05.
Of these, five were associated with increased risk: rs11694911 (1.29 RR, 1.10–1.51 95%
CI), rs2430420 (1.17 RR, 1.05–1.31 95% CI), rs10929669 (1.22 RR, 1.04–1.43 95% CI),
rs1049500 (1.38 RR, 1.10–1.73 95% CI), rs2357551 (1.13 RR, 1.01–1.27 95% CI); and two
were associated with decreased risk: rs13000916 (0.89 RR, 0.80–0.99 95% CI), rs818162
(0.86 RR, 0.76–0.97 95% CI) of adenoma recurrence. After accounting for multiple
comparisons using a 20% false discovery rate threshold (Q < 0.2), all seven associations
were still statistically significant. The previously investigated SNP, rs2302615, was not
associated with risk when the analysis was restricted to non-Hispanic whites, in agreement
with our previous results for all participants (17). Although an additive genetic model was
used for all SNPs in the analyses shown in Table 2, other models (i.e. dominant or recessive)
provided a better fit for several of the SNPs with a significant association suggesting larger
effect sizes (data not shown).
We also examined the association of adenoma recurrence with common haplotypes found
within 4 linkage blocks identified in this segment of the chromosome (see Table 3) to assess
the combined effect of correlated SNPs. In the first block, which contains 3 SNPs, a
haplotype (GTG) found in 10.6% of the study population (8.6% controls, 13.0% cases) was
associated with a 33% increased risk (1.33 RR, 1.12–1.57 95% CI, P=0.001) of adenoma
recurrence (per copy of the haplotype) compared to the most common haplotype in this
block (TCG). Another haplotype (GCA), occurring in 24% of the study population (23.1%
controls, 25.5% cases), was associated with a 14% increased risk that was borderline
statistically significant (1.14 RR, 1.00–1.30 95% CI, P=0.06). A test of the overall
association of genetic variation in block 1 with adenoma recurrence was statistically
significant (P=0.011). In the second block, which contains 4 SNPs, one haplotype (CCCT)
found in 23.3% of individuals (25.2% controls, 21.4% cases) was associated with a 15%
decreased risk (0.85 RR, 0.73–0.98 95% CI, P=0.029) and another (GTCC) found in 4.1% of
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individuals (2.7% controls, 5.7% cases) was associated with a 27% increased risk (1.27 RR,
1.01–1.61 95% CI, P=0.044) compared to the most common haplotype (GCCT). Overall,
genetic variation in this block was also statistically significantly associated with adenoma
recurrence (P=0.012). Genetic variation in block 3 was not associated with the outcome
(P=0.63). For the fourth block, one haplotype (CAAA) found in 26.1% of individuals
(23.8% controls, 28.9% cases) was associated with a 17% increased risk (1.17 RR, 1.02–
1.33 95% CI, P=0.021) per copy of the haplotype compared to the most common haplotype
in this block (GAAG), but the test of overall association was not statistically significant
(P=0.19).
Although the tag SNPs analyzed here were not in strong linkage disequilibrium (by
definition r2<0.8), some correlation still exists between them. Thus, in addition to the single
SNP and haplotype analyses described above, a multiple SNP analysis was used to assess
which SNPs in this chromosomal region were independently associated with risk of
adenoma recurrence. Starting with all SNPs in Table 2, those that were not statistically
significantly associated with risk were successively removed from a composite regression
model, until only 2 SNPs remained showing statistically significant independent associations
with risk: rs11694911 (1.29 RR, 1.08–1.53 95% CI, P=0.005) and rs2430420 (1.20 RR,
1.03–1.40 95% CI, P=0.022) using dominant genetic models (which provided a better fit
than additive or recessive models). The joint contribution of these two SNPs to adenoma risk
was highly statistically significant (P=0.0003) and the linkage disequilibrium between them
was very low (r2 = 0.05). In addition, there was no evidence for an interaction between the
two SNPs: their combined effect was essentially the sum of their excess risks. Thus, having
at least one risk allele at both loci (15% of the study population) was associated with a 53%
increased risk (1.53 RR, 1.24–1.90 95% CI, P<0.001) whereas having at least one risk allele
at only one loci (45% of the study population) was associated with a 24% increased risk
(1.24 RR, 1.12–1.38 95% CI, P<0.001) compared to having no risk alleles at either loci
(40% of the study population, referent group).
Finally, we evaluated whether there was evidence for an interaction between ODC
genotypes and aspirin treatment on risk for adenoma recurrence. Table 4 shows the
association of each genotype with adenoma risk stratified by aspirin treatment group. Two
SNPs (rs2430420 and rs28362380) had nominally statistically significant interactions,
although these findings were not corrected for multiple testing. For rs2430420, which had an
independent statistically significant main effect as described above, the variant allele was
not associated with risk in the placebo group, but was associated with an increased risk of
21% (1.21 RR, 0.98–1.49 95% CI) and 38% (1.38 RR, 1.15–1.66 95% CI) per allele in the
81 and 325 mg aspirin treatment groups, respectively. Conversely, when the effect of aspirin
was stratified by rs2430420 genotype (Table 5), 81 mg aspirin treatment appeared to be
protective among wild type homozygotes, with a risk reduction of 32% (RR 0.68, 0.50–0.94
95% CI) compared to placebo, but not among heterozygotes/variant homozygotes (RR 0.95,
0.75–1.20 95% CI). Notably, there was no evidence for interaction of aspirin treatment with
genotype at the other SNP that was independently associated with risk (rs11694911).
However, for rs28362380, which did not have a main effect on risk overall (see Table 2),
each variant allele was associated with a 25% risk reduction in the placebo group (0.75 RR,
0.53–1.04 95% CI), a 39% risk increase in the 81 mg/day aspirin treatment group (1.39 RR,
1.02–1.87 95% CI), but virtually no change in risk in the 325 mg/day aspirin treatment
group (1.03 RR, 0.80–1.35 95% CI) (Table 4). Conversely, when the effect of aspirin was
stratified by genotype (Table 5), 81 mg aspirin treatment was associated with a 25% risk
reduction in wild type homozyzgotes (0.75 RR, 0.61–0.92 95% CI) compared to placebo,
but not among heterozygotes/variant homozygotes (1.32 RR, 0.85–2.06 95% CI).
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Lastly, although we previously reported a statistically significant interaction between
rs2302615 and aspirin treatment (17), the interaction was not statistically significant in the
current analyses which differed from the prior analyses in that they were restricted to non-
Hispanic whites, were adjusted for age and sex and analyzed the aspirin treatment groups
separately (Tables 4 and 5). However, when we precisely mimicked the previous analysis by
assessing the combined aspirin treatment effect (81 and 325 mg doses together) stratified by
genotype using a dominant genetic model, the interaction was still not statistically
significant although the results were similar (not shown): specifically, in the current
analysis, as in the prior analysis, there was no risk reduction in the wild type homozygotes
(1.04 RR, 0.83–1.30 95% CI), while a 17% risk reduction was observed among
heterozygotes/variant homozygotes (0.83 RR, 0.66–1.04 95% CI, Pint=0.15) that was only
slightly smaller in magnitude than that reported previously (23% risk reduction, 0.77 RR,
0.63–0.95 95% CI, Pint=0.04, see (17)).
DISCUSSION
We observed that several common genetic variants in or near the ODC gene are associated
with risk of colorectal adenoma recurrence among non-Hispanic white participants in a
randomized aspirin trial. After adjustment for multiple comparisons, significant associations
between adenoma recurrence and genotype at seven tag SNPs remained using an additive
genetic model, including 5 downstream (rs13000916, rs11694911, rs2430420, rs10929669,
rs818162), 1 upstream (rs2357551) and 1 within the transcribed region (exon 12) of the
ODC gene (rs1049500). In addition, common haplotypes in three out of four haplotype
blocks were significantly associated with adenoma risk, as was overall variation in two of
the blocks. However, there was no evidence for combined allelic effects within a block since
the haplotype effect sizes were similar to that seen in the single SNP analyses. In a
composite (multiple SNP) analysis, only two of the SNPs were independently associated
with risk: having at least one variant allele was associated with increased risks of 20% for
rs2430420 (1.20 RR, 1.03–1.40 95% CI, P=0.022) and 29% for rs11694911 (1.29 RR, 1.08–
1.53 95% CI, P=0.005). In addition, in the 15% of the population with at least one variant
allele at both loci, risk was increased by 53% compared to individuals without any variant
alleles at these two loci (1.53 RR, 1.24–1.90 95% CI, P<0.001). There was also evidence for
an interaction between rs2430420 genotype and aspirin treatment since genotype was only
associated with increased risk in aspirin treated participants. Interestingly, another SNP
(rs28362380) without a main effect on risk, also appeared to interact with aspirin treatment.
These results provide additional support for the importance of the polyamine pathway in the
development of colorectal neoplasia, since common genetic variation in a potential
regulatory region just downstream of the ODC gene is associated with risk of adenoma
recurrence. Polyamines may play an important role in etiology of colorectal carcinogenesis
since DFMO treatment (in combination with sulindac) was highly effective in a
chemoprevention trial (7). ODC gene variants have not been identified in GWAS of
colorectal cancer performed to date even though the effect sizes and minor allele frequencies
seen here are of the same order of magnitude as for the SNPs detected by these studies (33,
34). It is possible that an intermediate outcome, such as adenoma, may show stronger
associations with genotype than cancer if the genotype effect is related to early events in
adenoma initiation or progression. Thus, it may be worthwhile to perform GWAS of
colorectal adenomas, as opposed to cancer, in future studies in order to identify (additional)
chemoprevention targets. However, it is also possible that the true genotype effect sizes are
smaller than we see here and, therefore, it will be important to replicate these findings in
other studies.
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Whether the SNPs (rs2430420 and rs11694911) identified in this study are themselves
causal, or are in linkage disequilibrium with unmeasured causal variants is not known.
However our results suggest that there are at least two causal variants near the ODC gene
that independently impact risk and whose effects are additive with each other. These results
highlight the potential importance of genetic variation in non-coding regions, which is likely
to be involved in the regulation of gene expression, and the gaps in our knowledge regarding
mechanisms for such effects. These findings are consistent with the results of numerous
GWAS studies performed to date, where the vast majority (about 80%) of “hits” (disease- or
trait-associated SNPs) were from non-coding introns and intergenic regions (35). To our
knowledge, the function of these SNPs (rs2430420 and rs11694911) has not been
investigated and potential gene regulatory mechanisms are not known. Notably, no SNPs
were in linkage disequilibrium (r2≥0.8) with these two SNPs in our dataset of 28 other SNPs
genotyped within 23 kb of the ODC gene. Also, no SNPs in the HAPMAP CEU dataset of
41 SNPs genotyped within 50 kb of the ODC gene were in linkage disequilibrium with
rs11694911 (note that rs2430420 is not in the HAPMAP dataset and so could not be
included in this type of analysis).
The mechanism by which common genetic variants in or near the ODC gene may affect the
efficacy of aspirin chemoprevention is also not known. However, it has been suggested
previously that aspirin, in addition to inhibiting the prostagladin pathway, may also induce
spermidine/spermine-N-acetyltransferase (SSAT) activity (16), which catalyzes the first step
in polyamine catabolism or excretion from the cell (36, 37). Aspirin and some other
NSAIDs, including sulindac, have been shown to stimulate polyamine catabolism in colon
cancer cells via induction of SSAT activity (38, 39). It has been suggested that polyamines
may play a role in the relationship between inflammation and carcinogenesis (40, 41).
Interestingly, in our randomized aspirin trial, 81 mg/day aspirin was effective in reducing
the recurrence of colorectal adenoma whereas 325 mg/day was not (21). The reason for this
is not clear, but may relate to differential pro- and anti-carcinogenic effects of aspirin at
different doses, which could involve differential effects on the polyamine pathway, although
this is speculation. Our results hint that the interaction between ODC genotype and aspirin
may differ by aspirin dose, which could lend support to this idea and could be explored in
future studies.
Previous work has focused only on a SNP (rs2302615) in the promoter region of the ODC
gene, near binding sites for transcription factors, that appears to affect transcriptional
activity (16, 42, 43). Among participants in the Wheat Bran Fiber Trial, individuals
homozygous for the variant allele had an approximately 50% reduced risk of colorectal
adenoma recurrence and appeared to have an enhanced risk reduction in response to aspirin
use compared to individuals that were homozygous wild type, although these associations
did not reach statistical significance (16). Similar results were found among participants in
the United Kingdom Colorectal Adenoma Prevention Trial (18). However, in our previous
analysis of all subjects in the Aspirin/Folate Polyp Prevention Study (regardless of race/
ethnicity), we found that genotype was not associated with a main effect on risk of adenoma
recurrence (17) consistent with the current analysis of non-Hispanic whites. Although we
previously reported a statistically significant interaction between genotype and aspirin
treatment in an unadjusted analysis using all subjects (17), the interaction is no longer
statistically significant after adjusting for age and sex and including only non-Hispanic
whites in the current analysis (see Table 5). The main difference was the adjustment for age,
as the magnitude of the effect was not attenuated and the interaction was still significant
after adjustment for sex and restriction to non-Hispanic whites. Notably, a published meta-
analysis analysis of these three studies (16–18) used raw (unadjusted) data (18). In light of
our findings, a more rigorous analysis of this SNP (rs2302615) may be warranted. Finally, it
is worth noting that this previously studied SNP is not correlated with the either of the two
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SNPs (rs2430420 and rs11694911) identified here to be independently associated with
adenoma risk (r2=0 and 0.01, respectively).
There are some limitations to the current analyses. Due to the size of the study population,
we had limited power, especially for investigating interactions with aspirin treatment. Also,
due to the limited sample size and power, we did not investigate associations with advanced
lesions (which occur much more rarely) or include minorities (individuals with a race or
ethnicity other than non-Hispanic whites). In addition, the study was performed on
individuals with a history of adenoma who may be at increased risk relative to the general
population undergoing screening or surveillance colonoscopy, potentially limiting the
generalizability of the findings. However, since adenoma prevalence in the general (middle-
aged or older) population is high, likely between 25–50% (44, 45), this is unlikely to be a
major limitation. Finally, multiple comparisons were conducted, which increases the
likelihood that some of our findings may be due to chance. Although the analyses of the
SNP main effects were adjusted for multiple comparisons (and were still statistically
significant) the tests for interactions with aspirin were not. Thus, we can be less certain that
the interactions discovered are not due to chance. However, this concern is mitigated to
some extent by the fact that these tests were chosen a priori, based on previous studies and a
biological rationale, and not as part of a data-dredging exercise.
This study also had several notable strengths. A single study pathologist reviewed all lesions
from trial participants, ensuring uniform endpoint ascertainment. Data on environmental
exposures and subject characteristics were collected in a detailed and uniform manner at the
time of participant enrollment. Aspirin treatment was randomly assigned, thereby ensuring
uniform exposure and minimizing concerns about differences between the treated and
placebo groups, which could confound the results. Subject compliance with study
procedures was excellent (21), including pill taking and avoidance of outside use of the
study agents. Finally, a comprehensive tag SNP approach was used to capture common
genetic variation throughout the ODC gene and adjacent chromosomal regions. This was
important for capturing genetic variation in potential regulatory regions that are likely to
influence gene expression through effects on transcriptional or translation efficiency.
This work suggests several potential lines of investigation for future studies. First, these
findings need to be replicated in other populations and with larger samples sizes. It would be
especially useful to investigate these effects in other populations with well-characterized or
randomized aspirin treatment with different doses, as well as in studies of colorectal cancer.
If these results are replicated, it will be important to try to identify the causal SNPs by
exploring the functionality of the SNPs identified here, especially rs2430420 and
rs11694911, and by sequencing this chromosomal region to ascertain unmeasured or rare
variants in linkage disequilibrium with these SNPs that may themselves be the causal
variants. In addition, given the strong evidence basis for both aspirin and DFMO in
colorectal chemoprevention, it will be valuable to genotype these SNPs in individuals that
are treated with these agents in future clinical studies in order to assess their impact on
efficacy. Finally, given the strong association of genetic variation in this region with race
and ethnicity, it will also be worthwhile to investigate these effects in minority populations,
especially African Americans and Hispanics.
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Flow diagram showing the numbers of participants from the Aspirin/Folate Polyp
Prevention Study that were included in this secondary analysis involving ODC genotyping.
The non-Hispanic whites shown here represent 85% of the total randomized population
(n=1121).
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The linkage disequilibrium (LD) block structure of the 19.33 kB genotyped region is shown
as determined using Haploview (26). The heavy black arrow on top shows the location of
the ODC gene (transcribed region). D’ values are shown for each pairwise comparison (dark
blocks without values are in complete LD, while lighter boxes without values are
“inconclusive”) (26).
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Table 1






No. of subjects (%) 792 (100) 422 (53.3) 370 (46.7)
Mean age at enrollment ± SD, y 57.83 ± 9.53 56.4 ± 9.5 59.4 ± 9.3 <0.001
Sex, No. (%)
    Male 507 (64.0) 250 (59.2) 257 (69.5)
0.003
    Female 285 (36.0) 172 (40.8) 113 (30.5)
Family history of colorectal cancer, No. (%)c
    No 397 (60.9) 218 (61.8) 179 (59.9)
0.24
    Yes 255 (39.1) 135 (38.2) 120 (40.1)
Follow-up time (mean ± SD), mod 32.8 ± 3.6 32.6 ± 3.1 33.0 ± 4.1 0.14
Aspirin treatment group, No. (%)
    Placebo 253 (31.9) 128 (30.3) 125 (33.8)
    81 mg Aspirin 271 (34.2) 161 (38.2) 110 (29.7) 0.04
    325 mg Aspirin 268 (33.8) 133 (31.5) 135 (36.5) 0.83
Folate treatment group, No. (%)
    Placebo 358 (45.2) 196 (46.5) 162 (43.8)
    1 mg Folate 367 (46.3) 192 (45.5) 175 (47.3) 0.51
    Not randomized to folate 67 (8.5) 34 (8.1) 33 (8.9) 0.55
a
Only participants self-identifying as “white, not of Hispanic origin” were included.
b
Tests for comparison between group with no adenoma and group with adenoma recurrence using two-sample t test for continuous variables and
Pearson χ2 test for categorical variables.
c
Family History data is missing for 140 subjects.
d
Months between randomization and follow-up colonoscopy.
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Table 3




RR (95% CI) Pa Pb
Block 1c
     TCG 47.2 / 41.6 1.00 (reference)
0.011
     GCA 23.1 / 25.5 1.14 (1.00–1.30) 0.06
     GCG 21.0 / 19.2 1.02 (0.88–1.17) 0.84
     GTG 8.5 / 13.0 1.33 (1.12–1.57) 0.001
     Rare 0.2 / 0.7 1.41 (0.70–2.81) 0.34
Block 2d
     GCCT 33.3 / 37.3 1.00 (reference)
0.012
     GCCC 31.0 / 29.7 0.91 (0.80–1.05) 0.20
     CCCT 25.2 / 21.4 0.85 (0.73–0.98) 0.029
     CCTT 7.3 / 5.8 0.82 (0.64–1.04) 0.11
     GTCC 2.7 / 5.7 1.27 (1.01–1.61) 0.044
     Rare 0.4 / 0.1 0.55 (0.13–2.32) 0.41
Block 3e
     TG 66.1 / 64.3 1.00 (reference)
0.63     TA 23.7 / 25.3 1.05 (0.93–1.20) 0.41
     CG 10.2 / 10.4 1.06 (0.89–1.27) 0.50
Block 4f
     GAAG 46.4 / 41.9 1.00 (reference)
0.19
     CAAA 23.8 / 28.9 1.17 (1.02–1.33) 0.021
     CGAG 21.4 / 20.1 1.02 (0.88–1.18) 0.81
     CAGA 7.3 / 7.4 1.06 (0.86–1.31) 0.57
     Rare 0.9 / 1.6 1.27 (0.86–1.31) 0.33
Abbreviations: RR, relative risk; CI, confidence interval
a
Per haplotype relative risk and Wald test P-value adjusted for age and sex.
b
Likelihood ratio test P-values for joint test of all haplotypes in the block.
c
Block 1 includes rs13000916, rs11694911 and rs2430419.
d
Block 2 includes rs818162, rs1049500, rs28362416 and rs7559979.
e
Block 3 includes rs28362380 and rs2302615.
f
Block 4 includes rs1728148, rs885815, rs2884211 and rs2357551.
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Table 4
Association of ODC genotypes with risk of adenoma recurrence stratified by aspirin treatment group, Aspirin/
Folate Polyp Prevention Study, 1994–2001
RR (95% CI)a
SNP Placebo 81 mg/day Aspirin 325 mg/day Aspirin Pint
rs13000916 0.89 (0.75–1.07) 0.94 (0.76–1.15) 0.84 (0.71–1.00) 0.76
rs11694911 1.40 (1.06–1.85) 1.24 (0.92–1.67) 1.31 (1.00–1.70) 0.82
rs2430419 0.91 (0.73–1.12) 1.13 (0.89–1.42) 1.27 (1.05–1.55) 0.08
rs2430420 0.99 (0.8201.20) 1.21 (0.98–1.49) 1.38 (1.15–1.66) 0.05
rs10929669 1.26 (0.94–1.69) 1.23 (0.92–1.66) 1.21 (0.94–1.56) 0.97
rs28362434 1.14 (0.91–1.44) 0.83 (0.62–1.11) 0.82 (0.65–1.04) 0.10
rs818162 0.94 (0.77–1.14) 0.77 (0.61–0.98) 0.84 (0.70–1.03) 0.45
rs1049500 1.42 (0.99–2.05) 1.53 (1.03–2.27) 1.16 (0.75–1.80) 0.63
rs28362416 0.63 (0.41–0.97) 0.79 (0.51–1.25) 1.19 (0.84–1.69) 0.08
rs7559979 1.01 (0.84–1.22) 1.15 (0.92–1.45) 0.98 (0.82–1.18) 0.50
rs28362380 0.75 (0.53–1.04) 1.39 (1.02–1.87) 1.03 (0.80–1.35) 0.03
rs2302615b 1.11 (0.91–1.36) 0.94 (0.73–1.21) 0.97 (0.79–1.19) 0.56
rs1728148 0.88 (0.73–1.06) 0.94 (0.76–1.15) 0.93 (0.78–1.10) 0.91
rs885815 1.13 (0.91–1.40) 0.86 (0.65–1.13) 0.86 (0.69–1.09) 0.19
rs2884211 0.95 (0.68–1.34) 1.06 (0.74–1.52) 1.06 (0.76–1.47) 0.89
rs2357551 1.05 (0.86–1.28) 1.15 (0.93–1.43) 1.22 (1.02–1.46) 0.56
Abbreviations: SNP, single nucleotide polymorphism; RR, relative risk; CI, confidence interval; Pint = P for interaction (between aspirin treatment
and genotype, modeled additively).
a
Per allele relative risk using an additive genetic model adjusted for age and sex.
b
Previously genotyped SNP (17)
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